Please check your internet connection and try again.
# Piperacillin/Tazobactam
## Overview
Piperacillin/tazobactam is a combination antibiotic consisting of piperacillin, a broad-spectrum penicillin-class beta-lactam antibiotic, and tazobactam, a beta-lactamase inhibitor. It is bactericidal and has activity against many gram-positive, gram-negative, and anaerobic bacteria, including many that produce beta-lactamases.
## Primary Indications
* Complicated intra-abdominal infections (cIAI)
* Complicated skin and skin structure infections (cSSSI)
* Community-acquired pneumonia (CAP)
* Nosocomial pneumonia
* Nosocomial intra-abdominal infections
* Febrile neutropenia (as part of combination therapy)
## Adult Dosing
The standard adult dose is 3.375 grams (piperacillin 3 grams / tazobactam 0.375 grams) or 4.5 grams (piperacillin 4 grams / tazobactam 0.5 grams) administered intravenously every 6 or 8 hours.
* **Common Dosing:** 3.375 g IV every 6 hours or 4.5 g IV every 8 hours.
* **Maximum Dose:** Generally, not to exceed 13.5 grams per day (4.5 g IV every 6 hours). Higher doses may be considered in severe infections based on clinical judgment and local protocols.
* **Duration:** Typically 7-14 days, depending on the infection and clinical response.
## Pediatric Dosing
Dosing is based on piperacillin component.
* **Patients ≥ 12 years:** Same as adult dosing.
* **Patients < 12 years:** 100 mg piperacillin component/kg (e.g., 87.5 mg/kg of piperacillin/tazobactam 8:1) IV every 8 hours or 125 mg piperacillin component/kg (e.g., 112.5 mg/kg of piperacillin/tazobactam 8:1) IV every 6 hours. Maximum dose generally 4.5 g every 6 hours.
* **Febrile Neutropenia in Pediatrics:** Dosing often based on piperacillin 75-100 mg/kg/dose (or 3.0-4.5 g/m²/day) IV every 6-8 hours, with tazobactam component proportional. Actual pediatric dosing can vary and should be guided by institutional protocols or expert consultation.
## Dose Adjustments
* **Renal Impairment (CrCl < 40 mL/min):** Reduce dose or extend interval.
* CrCl 20-40 mL/min: 2.25 g IV every 6 hours (3.375 g every 8 hours) or 3.375 g IV every 8 hours (4.5 g every 12 hours).
* CrCl < 20 mL/min: 2.25 g IV every 8 hours or 3.375 g IV every 12 hours.
* Hemodialysis: 2.25 g IV every 8 hours plus 0.75 g (tazobactam 0.09375 g) administered at the end of each hemodialysis session. Or 2.25 g IV every 6 hours with 0.75 g given after dialysis if receiving q6h dosing.
* **Hepatic Impairment:** No dose adjustment recommended, but use with caution.
## Contraindications
* Known severe hypersensitivity to piperacillin, tazobactam, other beta-lactam antibiotics, or any component of the formulation.
## Adverse Effects
* **Common:** Diarrhea, nausea, vomiting, rash, headache, insomnia, constipation, abdominal pain.
* **Serious:** Anaphylaxis, Clostridioides difficile-associated diarrhea (CDAD), Stevens-Johnson syndrome, toxic epidermal necrolysis, seizure (especially with high doses or renal impairment), interstitial nephritis, acute kidney injury, liver enzyme elevations, hematologic changes (e.g., neutropenia, thrombocytopenia, eosinophilia).
## Key Drug Interactions
* **Probenecid:** Increases piperacillin/tazobactam serum concentrations.
* **Neuromuscular Blocking Agents (e.g., vecuronium):** Piperacillin may prolong the neuromuscular blockade.
* **Warfarin:** May decrease the effect of warfarin; increased INR monitoring is recommended.
* **Methotrexate:** Piperacillin may decrease methotrexate clearance. Monitor methotrexate levels.
* **Aminoglycosides:** Generally compatible, but consider potential for antagonism with Pseudomonas aeruginosa and degradation of aminoglycosides in vitro. Separate administration if possible.
## Monitoring
* Renal function (baseline and periodically)
* Liver function tests
* Complete blood counts (especially with prolonged therapy or suspicion of hematologic adverse effects)
* Electrolytes
* Signs and symptoms of hypersensitivity reactions
* Signs and symptoms of C. difficile infection
* Clinical signs of infection resolution
## Clinical Pearls
* Piperacillin/tazobactam is administered via intravenous infusion, typically over 30 minutes. Longer infusions (e.g., 4 hours) may be used in some protocols, particularly for gram-negative coverage and critically ill patients.
* The 8:1 ratio of piperacillin to tazobactam (e.g., 3.375 g, 4.5 g) is most common. Other ratios exist.
* Reconstituted solutions are typically stable for 24 hours at room temperature or 48 hours if refrigerated. Specific stability depends on the diluent used.
* Discontinue immediately if hypersensitivity or severe C. difficile-associated diarrhea occurs.
* Adjust dose for renal impairment.
---
**Disclaimer:** This information is intended for healthcare professionals. It is essential to consult the most current prescribing information and relevant guidelines for complete and up-to-date details before making clinical decisions. Local protocols may dictate specific dosing strategies.
